August 13, 2020
A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potential treatment of adults with moderate-to-severe chronic hand eczema. Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. Stelara is now approved for pediatric patients, 6-11 years of age, with moderate to severe plaque psoriasis. Look for Rihanna’s new Fenty Skin line under the umbrella of skincare offerings.